https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/473 2026-07-03T23:41:53Z 2026-07-03T23:41:53Z Jun, Hyun Woong Song, Chang Myeon Park, Hae Jin Ji, Yong Bae Tae, Kyung https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/211043 2026-03-04T02:30:31Z 2026-02-01T00:00:00Z

Title: Serial Changes in Parotid Gland Volume and Symptoms After Radiation Therapy in Oropharyngeal Cancer Authors: Jun, Hyun Woong; Song, Chang Myeon; Park, Hae Jin; Ji, Yong Bae; Tae, Kyung Abstract: Objective: To evaluate the serial changes in the volume of the parotid gland and clinical symptoms after a course of radiation therapy (RT) in patients with oropharyngeal cancer. Methods: A total of 33 patients who were diagnosed with oropharyngeal cancer and had been treated with RT or concurrent chemoradiation therapy were evaluated. Parotid gland volumes were measured serially by head and neck computed tomography with contrast-enhanced images before RT, and 6 months, 1 year, and 2 years after RT. Patients also filled out EORTC (European Organization for the Research and Treatment of Cancer) QLQ-C30 questionnaires on the quality of life (QOL) at the same time. This questionnaire included questions about salivary gland function: dry mouth, sticky saliva, and taste disorder. Higher scores on EORTC questionnaire translates to worse QOL. Results: All patients received more than 60 Gy irradiation in total. The mean volume of parotid gland decreased from 23.30 mL before RT to 15.80 mL, 15.93 mL, and 16.67 mL after 6 months, 1 year, and 2 years, respectively (P < 0.001 between pre-RT and all other 3 periods). The scores on the QOL questionnaire were higher (worsened QOL) at all 3 times after radiation than in the pre-RT period. The mean score of QOL increased from pre-RT to 2 years post-RT: “dry mouth” from 1.65 to 2.70, “sticky saliva” from 1.19 to 2.00, and “taste disorder” from 1.12 to 1.94. All 3 of these parameters were correlated with the volume of the parotid gland (P < 0.005 each). Conclusions: The volume of the parotid gland decreases significantly after RT for oropharyngeal cancer and does not recover significantly for at least 2 years. There was a significant correlation between decreased parotid volume and a lower QOL involving salivation.

2026-02-01T00:00:00Z Koh, Hyeon Kang Park, Younghee Koo, Taeryool Cheong, Kwang-Ho Lee, Me Yeon Park, Hae Jin Kim, Kyoung Ju Park, Soah Han, Taejin Kang, Sei-Kwon Ha, Boram Yoon, Jai-Woong Young, Me Bae, Hoonsik https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/209259 2026-02-01T13:04:06Z 2025-11-01T00:00:00Z

Title: Comparison of Survival Outcomes and Toxicities Between Volumetric-modulated Arc Therapy and Conventional Radiotherapy in Early Glottic Cancer Authors: Koh, Hyeon Kang; Park, Younghee; Koo, Taeryool; Cheong, Kwang-Ho; Lee, Me Yeon; Park, Hae Jin; Kim, Kyoung Ju; Park, Soah; Han, Taejin; Kang, Sei-Kwon; Ha, Boram; Yoon, Jai-Woong; Young, Me; Bae, Hoonsik Abstract: Background/Aim: To compare survival outcomes and radiation-related toxicities between conventional radiotherapy (CvT) and volumetric-modulated arc therapy (VMAT) in patients with early glottic cancer. Patients and Methods: We reviewed 81 patients with Tis-T2N0 glottic cancer who underwent definitive radiotherapy between 2010 and 2018. CvT (N=47) was delivered using two opposing lateral beams (70 Gy in 35 fractions), while VMAT (N=34) utilized two arcs (65.25 Gy in 29 fractions). Hypothyroidism was defined as an elevated thyroid- stimulating hormone level with or without a decrease in free T4 or T3 levels. continued Results: The overall median follow-up time was 80.0 months and was longer in the CvT group (116.0 months) than in the VMAT group (45.3 months). Five-year local failure-free survival (95.4% vs. 84.5%, p=0.088), regional failure- free survival (93.0% vs. 94.1%, p=0.481), locoregional failure-free survival (90.9% vs. 84.7%, p=0.319), and overall survival (89.4% vs. 90.7%, p=0.575) were comparable between the CvT and VMAT groups, respectively. No increase in regional failure was observed in the VMAT group despite exclusion of the anterior level III neck. Most local failures in the VMAT group occurred near the original tumor site and were associated with T2 disease (p=0.015). Hypothyroidism occurred more frequently in the CvT group (53.5%) than in the VMAT group (25.9%, p=0.043). Carotid artery events were noted in three patients treated with CvT (6.4%), with none in the VMAT group. Conclusion: VMAT demonstrated comparable survival outcomes to CvT while significantly reducing the incidence of hypothyroidism and potentially lowering carotid artery events. VMAT may be considered a preferred modality to improve quality of life in patients with early glottic cancer.

2025-11-01T00:00:00Z 박혜진 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/215961 2026-07-02T04:02:54Z 2025-10-17T00:00:00Z

Title: Posttreatment nutritional assessment for predicting survival outcomes in patients with head and neck cancer treated with definitive radiotherapy Authors: 박혜진

2025-10-17T00:00:00Z Kim, Jae Sik Park, Younghee Park, Hae Jin Jang, Won Il Jeong, Bae Kwon Kim, Hunjung Chang, Ah Ram https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/209235 2026-02-01T13:02:21Z 2025-10-01T00:00:00Z

Title: Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer Authors: Kim, Jae Sik; Park, Younghee; Park, Hae Jin; Jang, Won Il; Jeong, Bae Kwon; Kim, Hunjung; Chang, Ah Ram Abstract: Background: Long-term data on the efficacy of robotic stereotactic body radiotherapy (SBRT) for localized prostate cancer (LPC) remain limited. This study aimed to evaluate the 10-year treatment outcomes of SBRT in LPC patients and identify key prognostic factors. Methods: A total of 82 patients with LPC who underwent five-fraction SBRT (doses of 35–37.5 Gy) were included. The median follow-up duration was 11.0 years (range, 3.3–15.9 years). Clinical outcomes, including the biochemical failure-free survival (BCFFS), clinical failure-free survival (CFFS), and prostate-specific antigen (PSA) kinetics, were analyzed to evaluate the impact of various clinical and treatment factors on prognosis. Results: The 10-year BCFFS and CFFS rates were 86.3% (95% confidence interval [CI], 78.6–94.8) and 86.7% (95% CI, 78.8–95.4), respectively. Nine cases of biochemical failure were observed, alongside local (n = 1), regional (n = 2), and distant (n = 5) metastases. The cancer-specific survival rate was 100%. The median PSA nadir was 0.09 ng/ml (range, 0.0–3.12 ng/ml) and the median interval to PSA nadir was 52.8 months (range, 0.4–170.2 months). There was a negative correlation between the time to the PSA nadir and the PSA nadir value (r = −0.233, p = 0.035). Daily SBRT was associated with improved BCFFS compared to every-other-day treatment (hazard ratio [HR], 0.220; 95% CI, 0.067–0.720; p = 0.012), while a longer interval to PSA nadir (≥ 5 years) was associated with better CFFS (HR, 0.120; 95% CI, 0.015–0.944; p = 0.044). Conclusions: Robotic SBRT for LPC demonstrates durable long-term efficacy. Daily treatment schedules and interval to PSA nadir were identified as crucial prognostic indicators. These findings highlight the importance of PSA kinetics in predicting treatment success following robotic SBRT.

2025-10-01T00:00:00Z